Koers BioSyent Inc. Other OTC
Aandelen
BIOYF
CA0906901081
Farmaceutische producten
Omzet 2024 * | 35 mln. 25,69 mln. 23,69 mln. | Omzet 2025 * | 38,7 mln. 28,41 mln. 26,19 mln. | Marktkapitalisatie | 107 mln. 78,33 mln. 72,21 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | - | Nettowinst (verlies) 2025 * | - | EV/omzet 2024 * | 3,05 x |
Nettoliquiditeiten 2024 * | - 0 0 | Nettoliquiditeiten 2025 * | - 0 0 | EV/omzet 2025 * | 2,76 x |
K/w-verhouding 2024 * |
16,5
x | K/w-verhouding 2025 * |
14,4
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 60,63% |
Recentste transcriptie over BioSyent Inc.
Managers | Titel | Leeftijd | Van |
---|---|---|---|
René C. Goehrum
CEO | Chief Executive Officer | 64 | 01-01-96 |
Robert March
DFI | Director of Finance/CFO | - | 10-09-18 |
Navid Ashrafi
CTO | Chief Tech/Sci/R&D Officer | - | 01-05-14 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Sara Elford
BRD | Director/Board Member | 53 | 08-01-18 |
René C. Goehrum
CEO | Chief Executive Officer | 64 | 01-01-96 |
Peter Lockhard
BRD | Director/Board Member | 60 | 01-06-02 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+40,73% | 739 mld. | |
+32,83% | 598 mld. | |
-6,30% | 353 mld. | |
+15,15% | 318 mld. | |
+4,05% | 285 mld. | |
+15,00% | 240 mld. | |
+9,78% | 210 mld. | |
-5,52% | 206 mld. | |
+6,17% | 164 mld. |